Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions

Archives of Surgery

Volumn 141, Issue 10, 2006, Pages 968-973

  Ćwik, Grzegorz ^a   Wallner, Grzegorz ^a   Skoczylas, Tomasz ^a   Ciechański, Aleksander ^a   Zinkiewicz, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER CLASSIFICATION; CONTROLLED STUDY; CYTOLOGY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PANCREAS TUMOR; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BIOPSY, FINE-NEEDLE; CA-125 ANTIGEN; CA-19-9 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33750075730     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.141.10.968     Document Type: Article

References (22)

1. Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma: imaging techniques and tumor markers. Pancreas. 1992;7:66-86.
2. Rosewicz S. Pancreatic carcinoma. Lancet. 1997;349:485-489.
3. DelMaschio A, Vanzulli A, Sironi S, et al. Pancreatic cancer vs chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy. Radiology. 1991;178:95-99.
4. Benini L, Cavallini G, Zordan D, et al. A clinical evaluation of monoclonal (CA 19-9, CA 50, CA 12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas. 1988;3:61-66.
5. Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology. 1998;45:253-259.
6. Yeh CH, Chen HM, Jan YY, Hwang TL, Jeng LB, Chen MF. Clinical analysis of inflammatory masses of the pancreatic head region. Hepatogastroenterology. 1998;45:2392-2398.
7. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of serologic marker, CA 19-9, in the diagnosis of pancreatic cancer. Ann Intern Med. 1989;110:704-709.
8. Tomazic A, Pegan V. Preoperative staging of periampullar cancer with US, CT, EUS and CA 19-9. Hepatogastroenterology. 2000;47:1135-1137.
9. Manabe T, Miyashita T, Ohshio G. Small carcinoma of the pancreas. Cancer. 1988;62:135-141.
10. Hayakawa T, Naruse S, Kitagawa M, et al. A prospective multicenter trial evaluating diagnostic validity of multivariate analysis and individual serum marker in differential diagnosis of pancreatic cancer from benign pancreatic diseases. Int J Pancreatol. 1999;25:23-29.
11. Okusaka T, Okada S, Sato T, et al. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Hepatogastroenterology. 1998;45:867-872.
12. Ohara K, Tatsuzaki H, Molotkova NG, et al. Utility of serum CA 19-9 monitoring in preoperative radiotherapy for pancreatic cancer. Hepatogastroenterology. 2001;48:859-863.
13. Willett CG, Daly WJ, Warshaw AL. CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg. 1996;172:350-352.
14. van den Bosch RP, van Eijck CH, Mulder PG, Jeekel J. Serum CA 19-9 determination in the management of pancreatic cancer. Hepatogastroenterology. 1996;43:710-713.
15. Cerwenka H, Aigner R, Quehenberger F, et al. Preoperative differential diagnosis of benign and malignant pancreatic lesion: the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B, CA 19-9 and CEA. Hepatogastroenterology. 1997;44:1117-1121.
16. Omar YT, Al-Nayeeb N, Dhar P, et al. Serum levels of CA 125 in patients with gastric intestinal cancers. Tumour Biol. 1989;10:316-323.
17. Gattani AM, Mandeli J, Bruckner HW. Tumor markers in patients with pancreatic carcinoma. Cancer. 1996;78:57-62.
18. Raedle J, Oremek G, Welker M, Roth WK, Caspary WF, Zeuzem S. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas. 1996;13:241-246.
19. Sakamoto K, Haga Y, Yoshimura R, Egami H, Yokoyama Y, Akagi M. Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. Gut. 1987;28:323-329.
20. Haglund C. Tumour marker antigen CA 125 in pancreatic cancer: a comparison with CA 19-9 and CEA. Br J Cancer. 1986;54:897-901.
21. Slesak B, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, van Dalen A, Einarsson R. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. Cancer. 2000;89:83-88.
22. Sellner F, Machacek E. The importance of tumour volume in the prognosis of radically treated periampullary carcinomas Eur J Surg. 1993;159:95-100.